治疗不耐药的NSCLC中对阿米万他马布的持久反应,其中包含EGFR和复杂MET突变:一个病例报告
Lauren Schmalz1, Chance Bloomer2, Wei Zhang3
1Department of Hematology/Oncology, Wake Forest University School of Medicine, 1 Medical Center Blvd, Winston-Salem, NC 27157, United States.
Lung cancer (Amsterdam, Netherlands)
|October 19, 2023
概括
一名患有晚期非小细胞肺癌 (NSCLC) 和EGFR和MET突变的患者对amivantamab有持久反应. 这凸显了先进基因测试的重要性,以指导复杂肺癌病例的治疗.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 遗传学 是一个遗传学.
背景情况:
- 向疗法已经改变了转移性非小细胞肺癌 (NSCLC) 治疗特定瘤驱动突变的患者.
- 管理并发突变和克服治疗耐药性仍然是NSCLC管理中的重大临床挑战.
- 表皮生长因子受体 (EGFR) 和介质细胞-表皮转变因子 (MET) 途径在NSCLC病变发生和治疗向方面至关重要.
研究的目的:
- 报告一个患有转移性NSCLC并发EGFR和MET突变的患者对阿米万塔马布的持续反应病例.
- 强调纵向下一代测序 (NGS) 在识别获得性抵抗机制方面的临床实用性.
- 强调对抗性机制的持续研究的需要,以告知未来的NSCLC治疗策略.
主要方法:
- 一名患有转移性NSCLC和记录的EGFR (L747_A750delinsP exon19删除) 和MET (D1228H,D1228N,D1228Y,Y1230H,MET放大) 突变的患者接受了amivantamab治疗.
- 使用纵向下一代测序 (NGS) 来监测突变状态并识别耐药性机制.
- 患者的治疗史包括基化疗,EGFR氨酸激酶抑制剂 (TKI),以及阿米万塔药前的组合TKI和MET抑制剂.
主要成果:
- 患者获得了对阿米万塔马布的持久反应,持续了14个月.
- 在经过多种先前治疗线路的记录后观察到这种反应.
- 该案例说明了在复杂,并发性瘤驱动突变和获得的耐药性的背景下成功管理.
结论:
- 艾米万他马布可以成为具有特定EGFR和MET突变并发性NSCLC患者的有效治疗选择,即使在其他疗法下疾病进展后.
- 纵向NGS测试对于检测不断演变的耐药性机制和指导NSCLC中随后的治疗决策至关重要.
- 需要进一步的研究来阐明NSCLC中针对性治疗的复杂耐药性机制,并开发更有效的治疗策略.
更多相关视频
09:38Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib
Published on: June 26, 2019
8.0K
07:59Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer
Published on: September 8, 2023
1.1K
相关概念视频
02:56Treatment Resistant Cancers
3.3K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.3K
02:50Combination Therapies and Personalized Medicine
4.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K
02:57Targeted Cancer Therapies
7.7K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.7K
02:38Mitogens and the Cell Cycle
6.5K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.5K